Medical Condition News

RSS

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

Geneva, situated at the heart of Europe, provides a fitting setting for the 10th Annual Spring Meeting of the European Society of Cardiology Council (ESC) on Cardiovascular Nursing and Allied Professionals (CCNAP), 12 - 13 March 2010, with its special theme: "Uniting to Improve Cardiovascular Practice".

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Study: There are still barriers to veterans getting full course of PTSD treatment

Although the Department of Veteran Affairs is rolling out treatments nationwide as fast as possible to adequately provide for newly diagnosed PTSD patients, there are still significant barriers to veterans getting a full course of PTSD treatment. The study is published in the latest issue of the Journal of Traumatic Stress.

11 Feb 2010

Celebrity promotes fundraising event fro cancer research

KIMBERLY WYATT from the "Pussycat Dolls" has shone brightly to promote Cancer Research UK's latest fundraising event by posing in a bespoke, illuminated dress designed especially for her

11 Feb 2010

Feeding tube use more likely at big, for-profit hospitals

Larger, for-profit hospitals may be using too many feeding tubes on patients with advanced dementia without improving the quality of their care, a study finds, according to HealthDay News/Business Week. "Our results suggest that decisions about feeding tubes are more about which hospital you go to than a decision-making process that really elicits and supports patient choice," said the physician who led the study, which appears in today's Journal of the American Medical Association.

11 Feb 2010

Operation Eyesight urges Canadians to make a difference on Valentine's Day

On Valentine's Day it is traditional to send cards, flowers or a special gift to the people we love. But this year, are you wondering if it's time to try something new? Consider making a tribute gift through Operation Eyesight - it's a powerful way to say "I care" while at the same time helping people in the developing world see a future free of blindness.

10 Feb 2010

$TZD drug may increase fracture risk in older women$

TZD drug may increase fracture risk in older women

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures.

10 Feb 2010

Women who take AdvaCAL calcium supplements have high bone density

With Osteoporosis an increasing concern among women of all ages, a recent report in the medical journal Osteoporosis International found that women taking the AAACa (AdvaCAL®) calcium supplements had the highest bone density increase among 32 different calcium studies conducted between 1977 and 2008.

10 Feb 2010

HealthYes! brings mobile screening services to Colorado

HealthYes!®, a leading preventive medical screening company, is bringing its life-saving mobile screening services to Colorado. Leveraging the most medically advanced, state-of-the-art equipment and techniques in the industry, HealthYes! screens its clients for life-threatening medical conditions and diseases including: heart disease, stroke, abdominal aortic aneurysm, peripheral artery disease, diabetes and liver disease along with osteoporosis.

10 Feb 2010

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

University of Adelaide researchers in Australia are finding new ways to block the movement of cells in the body which can cause autoimmune diseases and the spread of cancer.

10 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

Seaside Therapeutics granted U.S patent covering methods of treating autism

Seaside Therapeutics LLC today announced the issuance of U.S. patent 7,648,993 B2 (‘993 patent), which covers methods of treating autism with group 1 antagonists of the metabotropic glutamate receptor (mGluR) pathway. An earlier related patent, U.S. patent 6,890,931 B2 (‘931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

The Gamida Cell-Teva Joint Venture (JV) announced today that the Data Monitoring Committee (DMC) has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

10 Feb 2010

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.

10 Feb 2010

Researchers find differences in the biology of lung cancer between men and women

An analysis of genetic and clinical data for nearly 800 patients with non-small cell lung cancer has identified differences in genetic characteristics that are associated with age and sex specific patterns of increased or decreased recurrence-free survival, according to a study in the February 10 issue of JAMA.

10 Feb 2010

Medical Condition News

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

CINJ researchers develop new vaccine strategy for pancreatic cancer

Study: There are still barriers to veterans getting full course of PTSD treatment

Celebrity promotes fundraising event fro cancer research

Feeding tube use more likely at big, for-profit hospitals

Operation Eyesight urges Canadians to make a difference on Valentine's Day

TZD drug may increase fracture risk in older women

Women who take AdvaCAL calcium supplements have high bone density

HealthYes! brings mobile screening services to Colorado

Researchers study new ways to block movement of cells that cause autoimmune diseases and cancer

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Seaside Therapeutics granted U.S patent covering methods of treating autism

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

Researchers find differences in the biology of lung cancer between men and women

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News